Dual HER2 targeting was also investigated in the KRISTINE study, in which women with localized operable BC were randomized to receive neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCH-P) or experimental T-DM1-P. The gene discussed is ERBB2; the disease is breast cancer.